NanoString Technologies

Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Atlantic Coastal Acquisition Corp.; Charge Enterprises, Inc.; Sagaliam Acquisition Corp.; TG Venture Acquisition Corp.;

Retrieved on:

Monday, April 8, 2024

Common stock, NanoString Technologies, Cryptocurrency

Nasdaq also announced today that it will delist the common stock of Remark Holdings, Inc.

Key Points:

Nasdaq also announced today that it will delist the common stock of Remark Holdings, Inc.
Remark Holdings, Inc.’s securities were suspended on February 14, 2024, and have not traded on Nasdaq since that time.
Cyanotech Corporation’s securities were suspended on February 20, 2024, and have not traded on Nasdaq since that time.
Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series .

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on:

Thursday, April 4, 2024

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points:

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
The conference will be held in San Diego, April 5-10, 2024.
NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
“NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on:

Monday, April 1, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points:

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
“We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on:

Wednesday, March 27, 2024

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points:

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
(Graphic: NanoString)
A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.

Patient Square Capital, a Leading Health Care-Focused Investment Firm, Agrees to Acquire NanoString Technologies

Retrieved on:

Monday, March 11, 2024

NanoString Technologies, Inc. (OTC: NSTGQ) (“NanoString” or the “Company”), a leading provider of life science tools for discovery and translational research, today announced that it has reached an agreement with Patient Square Capital (“Patient Square”), a prominent health care investment firm, pursuant to which Patient Square will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process.

Key Points:

NanoString Technologies, Inc. (OTC: NSTGQ) (“NanoString” or the “Company”), a leading provider of life science tools for discovery and translational research, today announced that it has reached an agreement with Patient Square Capital (“Patient Square”), a prominent health care investment firm, pursuant to which Patient Square will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process.
Under the terms of the agreement, Patient Square intends to purchase substantially all assets of the Company’s global business operations as a going concern for $220 million.
“This agreement with Patient Square provides continuity for our scientific customers and employees, and represents an important step in our financial restructuring,” said Brad Gray, President & CEO of NanoString.
Patient Square is represented by Kirkland & Ellis LLP as counsel and Greenhill & Co as investment banker.

European UPC Court of Appeal Overturns Injunction Impacting NanoString’s CosMx Products, Company to Immediately Resume Sales in 16 EU Countries

Retrieved on:

Monday, February 26, 2024

The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.

Key Points:

The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.
“We believe that with today’s decision, the tide is turning in favor of NanoString and scientific freedom.
NanoString is evaluating its next steps in Germany in light of today’s decision from the UPC and for now the German injunction remains in place.
The CosMx SMI platform has been installed at approximately 180 customer sites to date.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on:

Thursday, February 8, 2024

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points:

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
“Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
“The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

Retrieved on:

Friday, January 5, 2024

Biotechnology, Health, Genetics, Science, Other Science, NanoString Technologies, Employment, Compensation, RSU

NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees.

Key Points:

NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees.
In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString’s Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString.
One-third of the RSUs vest on the first market trading day on or following the first anniversary of the grant date and one-third of the RSUs vest annually each year on the first market trading day on or after the second and third anniversaries of the grant date, subject to each employee’s continued service through each such date.
The inducement RSU awards were made outside of NanoString’s current equity plan, the 2022 Equity Incentive Plan, and under NanoString’s 2018 Inducement Equity Incentive Plan and related award agreements, but will be subject to terms and conditions generally consistent with those in the 2022 Equity Incentive Plan.

NanoString Comments on Delaware District Court Verdict

Retrieved on:

Sunday, November 19, 2023

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty.

Key Points:

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty.
“We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amended in our post-trial motions and then expect to appeal to the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes.
This verdict does not prevent NanoString from continuing to sell GeoMx products anywhere in the world.
NanoString remains fully dedicated to enabling scientists to map the universe of biology and ultimately saving patients’ lives.

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Retrieved on:

Thursday, November 9, 2023

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Key Points:

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.
The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University of Washington at NanoSymposium (NANO22.08) on Sunday, Nov. 12, from 2:45-3:00 PM EST.
“With this unprecedented capability, researchers will gain critical insights into single cell signaling for healthy and diseased brain tissue.
The opportunity for future patient benefit is enormous,” said Brad Gray, President and CEO of NanoString.